PortalPublikationenChildhood medulloblastoma

Childhood medulloblastoma

Standard

Childhood medulloblastoma. / Massimino, Maura; Biassoni, Veronica; Gandola, Lorenza; Garrè, Maria Luisa; Gatta, Gemma; Giangaspero, Felice; Poggi, Geraldina; Rutkowski, Stefan.

in: CRIT REV ONCOL HEMAT, Jahrgang 105, 09.2016, S. 35-51.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Massimino, M, Biassoni, V, Gandola, L, Garrè, ML, Gatta, G, Giangaspero, F, Poggi, G & Rutkowski, S 2016, 'Childhood medulloblastoma', CRIT REV ONCOL HEMAT, Jg. 105, S. 35-51. https://doi.org/10.1016/j.critrevonc.2016.05.012

APA

Massimino, M., Biassoni, V., Gandola, L., Garrè, M. L., Gatta, G., Giangaspero, F., Poggi, G., & Rutkowski, S. (2016). Childhood medulloblastoma. CRIT REV ONCOL HEMAT, 105, 35-51. https://doi.org/10.1016/j.critrevonc.2016.05.012

Vancouver

Massimino M, Biassoni V, Gandola L, Garrè ML, Gatta G, Giangaspero F et al. Childhood medulloblastoma. CRIT REV ONCOL HEMAT. 2016 Sep;105:35-51. https://doi.org/10.1016/j.critrevonc.2016.05.012

Bibtex

@article{80601dfa92c441c6a15fe290fbc59b83,
title = "Childhood medulloblastoma",
abstract = "Medulloblastoma accounts for 15-20% of childhood nervous system tumours. The risk of dying was reduced by 30% in the last twenty years. Patients are divided in risk strata according to post-surgical disease, dissemination, histology and some molecular features such as WNT subgroup and MYC status. Sixty to 70% of patients older than 3 years are assigned to the average-risk group. High-risk patients include those with disseminated and/or residual disease, large cell and/or anaplastic histotypes, MYC genes amplification. Current and currently planned clinical trials will: (1) evaluate the feasibility of reducing both the dose of craniospinal irradiation and the volume of the posterior fossa radiotherapy (RT) for those patients at low biologic risk, commonly identified as those having a medulloblastoma of the WNT subgroup; (2) determine whether intensification of chemotherapy (CT) or irradiation can improve outcome in patients with high-risk disease; (3) find target therapies allowing tailored therapies especially for relapsing patients and those with higher biological risk.",
keywords = "Journal Article, Review",
author = "Maura Massimino and Veronica Biassoni and Lorenza Gandola and Garr{\`e}, {Maria Luisa} and Gemma Gatta and Felice Giangaspero and Geraldina Poggi and Stefan Rutkowski",
note = "Copyright {\textcopyright} 2016 Elsevier Ireland Ltd. All rights reserved.",
year = "2016",
month = sep,
doi = "10.1016/j.critrevonc.2016.05.012",
language = "English",
volume = "105",
pages = "35--51",
journal = "CRIT REV ONCOL HEMAT",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

RIS

TY - JOUR

T1 - Childhood medulloblastoma

AU - Massimino, Maura

AU - Biassoni, Veronica

AU - Gandola, Lorenza

AU - Garrè, Maria Luisa

AU - Gatta, Gemma

AU - Giangaspero, Felice

AU - Poggi, Geraldina

AU - Rutkowski, Stefan

N1 - Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

PY - 2016/9

Y1 - 2016/9

N2 - Medulloblastoma accounts for 15-20% of childhood nervous system tumours. The risk of dying was reduced by 30% in the last twenty years. Patients are divided in risk strata according to post-surgical disease, dissemination, histology and some molecular features such as WNT subgroup and MYC status. Sixty to 70% of patients older than 3 years are assigned to the average-risk group. High-risk patients include those with disseminated and/or residual disease, large cell and/or anaplastic histotypes, MYC genes amplification. Current and currently planned clinical trials will: (1) evaluate the feasibility of reducing both the dose of craniospinal irradiation and the volume of the posterior fossa radiotherapy (RT) for those patients at low biologic risk, commonly identified as those having a medulloblastoma of the WNT subgroup; (2) determine whether intensification of chemotherapy (CT) or irradiation can improve outcome in patients with high-risk disease; (3) find target therapies allowing tailored therapies especially for relapsing patients and those with higher biological risk.

AB - Medulloblastoma accounts for 15-20% of childhood nervous system tumours. The risk of dying was reduced by 30% in the last twenty years. Patients are divided in risk strata according to post-surgical disease, dissemination, histology and some molecular features such as WNT subgroup and MYC status. Sixty to 70% of patients older than 3 years are assigned to the average-risk group. High-risk patients include those with disseminated and/or residual disease, large cell and/or anaplastic histotypes, MYC genes amplification. Current and currently planned clinical trials will: (1) evaluate the feasibility of reducing both the dose of craniospinal irradiation and the volume of the posterior fossa radiotherapy (RT) for those patients at low biologic risk, commonly identified as those having a medulloblastoma of the WNT subgroup; (2) determine whether intensification of chemotherapy (CT) or irradiation can improve outcome in patients with high-risk disease; (3) find target therapies allowing tailored therapies especially for relapsing patients and those with higher biological risk.

KW - Journal Article

KW - Review

U2 - 10.1016/j.critrevonc.2016.05.012

DO - 10.1016/j.critrevonc.2016.05.012

M3 - SCORING: Journal article

C2 - 27375228

VL - 105

SP - 35

EP - 51

JO - CRIT REV ONCOL HEMAT

JF - CRIT REV ONCOL HEMAT

SN - 1040-8428

ER -